FPH reactivates dividend reinvestment plan
News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)
Fisher & Paykel Healthcare reactivates dividend reinvestment plan
Auckland, New Zealand, 29 November 2022 - Fisher & Paykel Healthcare Corporation Limited
(NZX:FPH, ASX:FPH) announced today that it is reactivating its dividend reinvestment plan (DRP)
for eligible shareholders residing in New Zealand, Australia and the United Kingdom.
Under the reactivated DRP, eligible shareholders may elect to reinvest all or part of their cash
dividends in additional shares. A 3% discount will be applied when determining the price per share
of shares issued under the DRP and will be applied in respect of the 2023 interim dividend and
future dividends, until such time as the directors determine otherwise.
Shareholders that previously opted into the plan will remain enrolled unless they terminate their
participation online at https://investorcentre.linkgroup.nz/ or by completing a cancellation form
available upon request from the company’s registrar, Link Market Services.
Shareholders not previously enrolled who wish to participate in respect of the FY2023 interim
dividend will need to opt into the plan via Link Market Services’ website at
https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 12
December 2022. The plan offer document and participation form are available on the company’s
website at www.fphcare.com/drp.
The strike price is calculated as the volume-weighted average sale price for an ordinary share,
calculated on all price-setting trades of shares which took place through the NZX Main Board over a
period of five trading days immediately following the dividend record date of 9 December 2022. The
company will issue an announcement of the strike price, inclusive of the 3% discount, once
calculated.
Fisher & Paykel Healthcare first introduced a dividend reinvestment plan in 2009 before suspending
it in 2019.
For more information, please contact Link Market Services at operations@linkmarketservices.co.nz
or +64 9 375 5998.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com.
Media & Investor Contacts:
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 27 807 8073
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PFI — Property for Industry Limited: Tenant Commitment to Kick Start Springs Road Redevelopment2022-12-18
“NZX and media announcement — 19 December 2022 Page 1 TENANT COMMITMENT TO KICK START SPRINGS ROAD REDEVELOPMENT Property for Industry Limited (PFI, the Company) is pleased to announce that existing tenant Fisher & Paykel Appliances has committed to the first…”
- KFL — Kingfish Limited: DIVIDEND REINVESTMENT PLAN PRICE DETERMINED2022-12-08
“9 December 2022 DIVIDEND REINVESTMENT PLAN PRICE DETERMINED Kingfish Limited (Kingfish) advises that the share price used to calculate entitlements under the Dividend Reinvestment Plan (the DRP) has been set at $1.3472. This is the volume weighted average price of all…”
- KFL — Kingfish Limited: DIVIDEND REINVESTMENT PLAN PRICE DETERMINED2022-09-14
“15 September 2022 DIVIDEND REINVESTMENT PLAN PRICE DETERMINED Kingfish Limited (Kingfish) advises that the share price used to calculate entitlements under the Dividend Reinvestment Plan (the DRP) has been set at $1.5238. This is the volume weighted average price of al…”